Abstract | AIM: METHODS: A total of 48 EE patients were enrolled and randomized into two treatment groups under 8-wk therapy: 25 receiving esomeprazole, while another 23 receiving omeprazole treatment. Finally, 44 completed the whole 8-wk therapy. RESULTS: The difference in healing EE between two groups was 22.7% (72.7% vs 50.0%), not reaching significant value (P = 0.204). The median of the first time needed in relieving heartburn sensation was 1 d for both groups and the remission rates for heartburn on the 1st d after treatment were 77.3% and 65%, respectively (NS). The scores of various reflux relieving symptoms evaluated either by patients or by investigators were not different. Regarding drug safety, 28% of esomeprazole group and 26.1% of omeprazole group reported at least one episode of adverse effects, while constipation and skin dryness were the common side effects in both groups (NS). CONCLUSION:
|
Authors | Chih-Yen Chen, Ching-Liang Lu, Jiing-Chyuan Luo, Full-Young Chang, Shou-Dong Lee, Yung-Ling Lai |
Journal | World journal of gastroenterology
(World J Gastroenterol)
Vol. 11
Issue 20
Pg. 3112-7
(May 28 2005)
ISSN: 1007-9327 [Print] United States |
PMID | 15918199
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Ulcer Agents
- Capsules
- Tablets
- Omeprazole
- Esomeprazole
|
Topics |
- Administration, Oral
- Adult
- Aged
- Anti-Ulcer Agents
(administration & dosage, adverse effects)
- Capsules
- Double-Blind Method
- Esomeprazole
- Esophagitis, Peptic
(drug therapy)
- Female
- Heartburn
(drug therapy)
- Humans
- Male
- Middle Aged
- Omeprazole
(administration & dosage, adverse effects)
- Prospective Studies
- Tablets
|